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Abstract
In 2006, two rotavirus vaccines were licensed. We summarize the impact of rotavirus vaccination 
on hospitalizations and deaths from rotavirus and all-cause acute gastroenteritis (AGE) during the 
first 10 years since vaccine licensure, including recent evidence from high child mortality 
countries. We used standardized guidelines (PRISMA) guidelines to identify observational 
evaluations of rotavirus vaccine impact among children <5 years of age that presented at least 12 
months of pre- and post-vaccine introduction surveillance data. We identified 57 articles from 27 
countries. Among children <5 years of age, the median percent reduction in AGE hospitalizations 
was 38% overall and 41%, 30%, 46% in low, medium, and high child mortality countries, 
respectively. Hospitalizations and ED visits due to rotavirus AGE were reduced by a median of 
67% overall and 71%, 59%, and 60% in low, medium and high child mortality countries, 
respectively. Implementation of rotavirus vaccines has substantially decreased hospitalizations 
from rotavirus and all-cause AGE.
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Introduction
Rotavirus accounts for about 40% of acute gastroenteritis (AGE) hospitalizations in children 
<5 years of age worldwide [1]. Since two live, oral rotavirus vaccines for infants were 
licensed in 2006, more than 80 countries have introduced rotavirus vaccine into their 
national routine immunization programs (Figure 1). Rotarix (RV1, GSK Biologics, 
Rixensart, Belgium) is a two-dose monovalent human rotavirus vaccine and RotaTeq (RV5, 
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Merck and Co., Westpoint, PA) is a three-dose pentavalent bovine-human reassortant 
rotavirus vaccine. These two rotavirus vaccines, as well as three nationally licensed rotavirus 
vaccines, are available subnationally and on the private market in additional countries.
Initially, in 2006, the World Health Organization (WHO) recommended rotavirus vaccine 
introductions only in high and middle income countries in regions with available efficacy 
data and with strong existing vaccination delivery infrastructure [2–4]. Early introducing 
countries in the Americas, Europe, and Australia reported large declines in rotavirus diarrhea 
and all-cause AGE hospitalizations and mortality shortly following national vaccine 
introduction [5–7]. With the availability of additional efficacy data from low income 
countries in Africa and Asia, WHO extended their routine rotavirus vaccine 
recommendation to all countries in 2009 [8, 9].
Previous reviews have summarized the impact of rotavirus vaccines on hospitalizations and 
deaths from diarrhea, but the data have been limited to a few years immediately following 
vaccine introduction primarily from the early introducing high and middle income countries 
[5–7]. We summarize the impact of rotavirus vaccination on hospitalizations and deaths 
from rotavirus and AGE during the first 10 years since vaccine licensure, including recently 
published evidence from low income countries with high child mortality that have 
introduced rotavirus vaccine.
Methods
Search strategy and selection criteria
We identified articles published between January 1, 2006 and December 6, 2016 by 
searching for the terms “rotavirus” and either “vaccin*” or “immuni*” in the PubMed 
database per the PRISMA guidelines [10]. We included post-licensure, observational 
evaluations of rotavirus vaccine impact on rotavirus AGE or all-cause AGE among children 
<5 years of age in countries where RV1 or RV5 had been licensed (Figure 2). We excluded 
studies if they were not relevant to our question, such as those addressing safety, 
programmatic considerations, parent or healthcare provider knowledge attitudes and 
practices, laboratory methods, vaccine effectiveness, and economic impact. We excluded 
articles that did not present an overall impact estimates, including those that compared 
subnational populations or those that presented rotavirus strain-specific impact. We also 
excluded articles that included a pediatric population but did not specify the age group. We 
included studies that presented at least 12 months of pre- and post-vaccine introduction 
surveillance data. When updated analyses from the same dataset were available in separate 
publications, we included all peer-reviewed articles.
Data abstraction
We developed a standardized data abstraction form, and two reviewers (EB and CJ) 
independently abstracted information on vaccine licensure and national rotavirus vaccine 
introduction, the type and duration of surveillance, the number and age groups of 
participants, and reported outcomes; discrepancies were reconciled. We developed a 
database using Microsoft Excel 2013, which included information related to annual changes 
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in the percentage of rotavirus-positive laboratory specimens as well as changes in rotavirus 
AGE and all-cause AGE hospitalizations and mortality. As this review focuses on the overall 
impact of rotavirus vaccines, we did not distinguish between the impact of RV1 and RV5. 
Using UNICEF 2014 <5 child mortality rates, we created three mortality strata where low 
mortality countries were defined as those with rates in the lowest quartile, medium mortality 
countries as those in the second lowest quartile, and high mortality countries as those in the 
highest two quartiles [11]. The mortality rate for children <5 years of age ranged from 1.9 to 
7 deaths per 1,000 live births in the ‘low mortality’ strata, from 8 to 17 in the ‘medium 
mortality’ strata and from 18 to 157 in the ‘high mortality’ strata in 2015. Full course 
rotavirus vaccine coverage among infants was based on the median UNICEF estimate for the 
final year of the study [12].
Data Analysis
We performed these analyses using SAS 9.4 Figures were created using R v2.7, Quantum 
GIS v2.8, and Microsoft Excel. When individual years were presented, estimates were 
included starting with the first full year after introduction, referred to as ‘year 1’.
Results
We included 57 articles reporting on 59 data sources from 27 countries in this analysis; two 
articles reported data from multiple countries (Figure 1, Supplementary Table 1). Of these 
data sources, 37 were from countries using RV1 only, five from countries using RV5 only, 
and 17 from countries using both vaccines. Of these, 53 reported results from inpatient or 
ED settings, 26, 13, and 14 from low, medium, and high mortality countries, respectively; 12 
reported mortality results, 11 and 5 from medium and high mortality countries, respectively.
Of the 53 reports from inpatient or ED settings in countries with national rotavirus vaccine 
introduction, the median number of years of follow-up after vaccine introduction was 3 
(range: 1, 9); the median was 3, 4, and 3 post-vaccine introduction years in low, medium, 
and high child mortality strata countries, respectively. Overall, the median UNICEF estimate 
of the full course rotavirus vaccine coverage among infants for the final year of evaluation 
was 83% (range: 44%, 98%); the median coverage was 77%, 83%, and 85% in low, medium, 
and high child mortality strata countries, respectively.
Among children <1 year of age, the median percent reduction in AGE hospitalizations 
and/or ED visits was 32% (range: 5, 63; n=20) overall and 36%, 28%, 33% in low (n=6), 
medium (n=7) and high (n=7) child mortality countries, respectively (Figure 3). Among 
children <5 years of age, the median percent reduction in AGE hospitalizations and/or ED 
visits was 38% (range: 5, 53; n=25) overall and 41%, 30%, 46% in low (n=8), medium (n=9) 
and high (n=8) child mortality countries, respectively.
Reductions in AGE mortality were reported in medium and high child mortality countries; 
no estimates have been published from low child mortality countries. The median reduction 
in AGE mortality among children <1 year of age was 31% (range: 0, 64; n=14) overall; in 
medium (n=9) and high (n=5) child mortality strata countries, it was 45% and 30%, 
respectively (Figure 4). The median reduction in AGE mortality in children <5 years was 
Burnett et al. Page 3
J Infect Dis. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
42% (range: 3, 64; n=14) overall; in medium (n=11) and high (n=3) child mortality strata 
countries, it was 50% and 36%, respectively. None of the articles examined reductions in 
mortality due to rotavirus specifically.
Hospitalizations and ED visits due to laboratory-confirmed rotavirus AGE were reduced by 
a median of 80% (range: 25, 89; n=20) among children <1 year of age overall and by 80%, 
78% and 46% in countries with low (n=15), medium (n=3), and high (n=2) child mortality, 
respectively. Among children <5 years of age, rotavirus AGE hospitalizations and ED visits 
were reduced by 67% (range: 18, 84; n=21) overall and by 71%, 59%, and 60% in low 
(n=14), medium (n=2), and high (n=5) child mortality, respectively.
Four evaluations reported the percentage of rotavirus positive specimens among children <1 
year of age over time, with 0, 1, and 3 estimates from low, medium, and high mortality strata 
countries, respectively. The median rotavirus positivity among children <1 year of age 
before vaccine introduction was 43%; it was 23% the first year and 17% the second year 
after introduction (Figure 5). This represents median reductions of 46% and 60%, 
respectively. Nine estimates of rotavirus positivity were reported among children <5 years of 
age over time, with 2, 2, and 5 estimates from low, medium, and high mortality strata 
countries, respectively. The median rotavirus positivity among children <5 years of age 
before vaccine introduction was 40%; it was 21% the first year and 19% the second year 
after introduction. This represents reductions of 48% and 53% in the median rotavirus 
positivity, respectively. After rotavirus vaccine introduction, we also noted an increase in the 
percent reduction in rotavirus hospitalizations and ED visits over time, though this was not 
evident in AGE hospitalizations (Figures 6A and 6B).
Indirect effects in older unvaccinated children
We identified four datasets that reported reductions in AGE hospitalizations in 0–11 months 
and 12–59 months of age subgroups in the year following rotavirus vaccine introduction 
(Figure 7a). In this time frame, all of the 0–11 month old children but only a very small 
proportion of 12–59 month old children (primarily in the 12–23 month age group) would 
have been eligible for vaccination. Reductions were observed in both age groups in all 
datasets, though these reductions were higher in the older age group than in the 0–11 month 
age group in two datasets from Panama. Seven articles reported reductions in rotavirus 
hospitalizations in the year following rotavirus vaccine introduction with 0–11 months, 12–
23 months and 24–59 months of age subgroups (Figure 7b). In the US and Moldova, 
reductions were comparable for all three age groups. In Armenia, Belgium, and Ghana, 
reductions were modest in the 24–59 month age group. We saw an increase in rotavirus 
hospitalizations in Austria in the 24–59 month age group and in Tanzania in the 12–23 
month age group.
Discussion
We found substantial reductions in rotavirus and all-cause AGE hospitalizations and AGE 
mortality among children <1 year of age and <5 years of age in publications from 27 
countries that introduced rotavirus vaccine into their national routine immunization 
programs since 2006. Proportional reductions in rotavirus AGE hospitalizations were larger 
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than reductions in all-cause AGE hospitalizations. Generally, there were minimal differences 
in impact between <1 year and <5 year age groups. This is likely because the highest disease 
burden is in the youngest children and estimates from this literature review included time 
periods after rotavirus vaccine introduction where most age groups among children <5 years 
would have been age eligible for vaccination. Similar reductions were seen across mortality 
strata. It is particularly encouraging to see the large impacts in low income settings given 
concerns about vaccine performance. Among children hospitalized for diarrhea, the 
percentage of specimens that tested positive for rotavirus decreased during the two years 
following rotavirus vaccine introduction in both age groups. In several but not all studies, we 
observed reductions in rotavirus and AGE hospitalizations in age groups explicitly not 
eligible for vaccination, indicating evidence of indirect protection. As the mortality impact 
and herd benefits had not been assessed in trials, so these post-licensure findings are 
noteworthy.
This literature review has several limitations. First, published data are limited on vaccination 
impact on mortality; no studies have been published from high burden settings and limited 
data are available from low and medium burden settings. Second, while comparable 
endpoints were reported, there was some variation in protocol and analysis methods in the 
papers. For example, some publications presented annual hospitalization reductions and 
others presented multi-year summaries. This variability in reporting of findings led to some 
sparseness in our data and reduced nuance in our results. Finally, many articles did not 
present specific age groups, making it difficult to assess indirect effects and potentially 
diluting the reported impact in our main analysis.
Our results show the marked reductions on rotavirus hospitalization and AGE 
hospitalizations and mortality in a range of child mortality settings since the licensure of 
rotavirus vaccines a decade ago. Future research is needed to address the impact of rotavirus 
vaccine on hospitalizations in countries in Asia, indirect impact on age groups not targeted 
for vaccination, particularly in high child mortality settings, and the percentage of stool 
specimens positive for rotavirus for additional years post-introduction to provide a more 
complete and nuanced description of rotavirus vaccine impact.
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Figure 1. 
Map of rotavirus vaccine national introductions and estimates of rotavirus vaccine impact by 
individual countries.
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Figure 2. 
Article review and selection process.
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Figure 3. 
Reduction in AGE hospitalizations by age group and country's child mortality strata
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Figure 4. 
Reduction in AGE deaths by age group and country's child mortality strata
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Figure 5. 
Percentage of specimens positive for rotavirus by age group
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Figure 6. 
A. Reduction in AGE hospitalizations by age group and country's child mortality strata over 
time
B. Reduction in rotavirus hospitalizations by age group and country's child mortality strata 
over time
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Figure 7. 
a. Reduction in AGE hospitalizations by age group in the first full year after vaccine 
introduction.
b. Reduction in rotavirus hospitalizations by age group in the first full year after vaccine 
introduction
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